Open Access

Inhibitory effect of NVP‑BKM120 on cholangiocarcinoma cell growth

  • Authors:
    • Sureerat Padthaisong
    • Hasaya Dokduang
    • Supak Yothaisong
    • Anchalee Techasen
    • Nisana Namwat
    • Puangrat Yongvanit
    • Narong Khuntikeo
    • Attapol Titapun
    • Sakkarn Sangkhamanon
    • Watcharin Loilome
  • View Affiliations

  • Published online on: May 31, 2018     https://doi.org/10.3892/ol.2018.8848
  • Pages: 1627-1633
  • Copyright: © Padthaisong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Abnormal activation of the phosphatidylinositol 3‑kinase (PI3K) pathway has been demonstrated in certain types of cancer, including cholangiocarcinoma (CCA). This pathway may therefore be a promising target for CCA treatment. The present study assessed the inhibitory effect of NVP‑BKM120, a pan‑class I PI3K inhibitor, on CCA cell growth. This inhibitory effect was determined using CCA cell lines and in CCA‑inoculated mice. The result from sulforhodamine B (SRB) assay demonstrated that NVP‑BKM120 treatment inhibited CCA cell growth in a dose‑dependent manner, even at the lowest tested concentration. The in vivo study revealed that oral administration of NVP‑BKM120 (10 or 30 mg/kg) to CCA‑inoculated nude mice led to a reduction in tumor growth when compared with controls, which was indicated by an immunohistochemical assay for Ki67 expression. In addition, the result from TUNEL assay demonstrated that NVP‑BKM120 induced cancer cell death without any signs of toxicity, which indicated by the body weight of mice (data not shown). Western blot analysis demonstrated that NVP‑BKM120 inhibited CCA cell growth by suppressing RAC serine/threonine protein kinase/mechanistic target of rapamycin activation and inhibiting the phosphorylation of phosphatase and tensin homolog, which is the inactivation form of the negative regulator of this pathway. Therefore, the results of the present study indicated that NVP‑BKM120 should be considered as a therapeutic agent against CCA that could be used to improve treatment.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Padthaisong S, Dokduang H, Yothaisong S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Sangkhamanon S, Loilome W, Loilome W, et al: Inhibitory effect of NVP‑BKM120 on cholangiocarcinoma cell growth. Oncol Lett 16: 1627-1633, 2018
APA
Padthaisong, S., Dokduang, H., Yothaisong, S., Techasen, A., Namwat, N., Yongvanit, P. ... Loilome, W. (2018). Inhibitory effect of NVP‑BKM120 on cholangiocarcinoma cell growth. Oncology Letters, 16, 1627-1633. https://doi.org/10.3892/ol.2018.8848
MLA
Padthaisong, S., Dokduang, H., Yothaisong, S., Techasen, A., Namwat, N., Yongvanit, P., Khuntikeo, N., Titapun, A., Sangkhamanon, S., Loilome, W."Inhibitory effect of NVP‑BKM120 on cholangiocarcinoma cell growth". Oncology Letters 16.2 (2018): 1627-1633.
Chicago
Padthaisong, S., Dokduang, H., Yothaisong, S., Techasen, A., Namwat, N., Yongvanit, P., Khuntikeo, N., Titapun, A., Sangkhamanon, S., Loilome, W."Inhibitory effect of NVP‑BKM120 on cholangiocarcinoma cell growth". Oncology Letters 16, no. 2 (2018): 1627-1633. https://doi.org/10.3892/ol.2018.8848